Supplemental material
Expert Opinion on Drug Safety
Volume 21, 2022 - Issue 10
Original Research
Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study
Daisuke Yabea Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan;b Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kobe, Japan;c Division of Molecular and Metabolic Medicine, Kobe University Graduate School of Medicine, Kobe, Japan;d Center for Healthcare Information Technology, Tokai National Higher Education and Research System, Nagoya, Japan
https://orcid.org/0000-0002-5334-7687View further author information
https://orcid.org/0000-0002-5334-7687View further author information, , , &